Collegium Pharmaceutical Inc (NASDAQ:COLL) insider Alison B. Fleming sold 6,928 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total transaction of $132,116.96. Following the completion of the transaction, the insider now directly owns 32,651 shares of the company’s stock, valued at approximately $622,654.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Collegium Pharmaceutical Inc (NASDAQ COLL) traded down $0.27 during mid-day trading on Friday, hitting $20.02. 773,815 shares of the stock were exchanged, compared to its average volume of 354,849. Collegium Pharmaceutical Inc has a twelve month low of $7.37 and a twelve month high of $21.38.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The business had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The company’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.13) earnings per share. research analysts forecast that Collegium Pharmaceutical Inc will post -2.52 EPS for the current fiscal year.

A number of research firms have weighed in on COLL. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, December 7th. Needham & Company LLC lifted their price objective on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, December 5th. They noted that the move was a valuation call. Jefferies Group lifted their price objective on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 5th. Finally, BidaskClub cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Collegium Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $23.33.

Several hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors increased its stake in shares of Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after purchasing an additional 2,802 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Collegium Pharmaceutical by 12.7% during the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock worth $365,000 after purchasing an additional 3,285 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Collegium Pharmaceutical by 12.8% during the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after purchasing an additional 5,136 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Collegium Pharmaceutical by 38.4% during the second quarter. The Manufacturers Life Insurance Company now owns 18,621 shares of the specialty pharmaceutical company’s stock worth $233,000 after purchasing an additional 5,167 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Collegium Pharmaceutical by 21.5% during the second quarter. California State Teachers Retirement System now owns 40,195 shares of the specialty pharmaceutical company’s stock worth $503,000 after purchasing an additional 7,100 shares in the last quarter. 79.98% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-insider-sells-132116-96-in-stock/1805932.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.